\n<\/p>\n
I enjoyed reading an interesting study from the Journal of the American Academy of Dermatology addressing whether or not oral steroids are helpful when added with JAK inhibitors. The focus here was on the JAK inhibitor baricititinib. <\/p>\n
The two key points to take from this study are:<\/p>\n
1. Adding short-course systemic corticosteroids before or alongside baricitinib did not improve 24-week treatment outcomes in patients with moderate-to-severe alopecia areata.<\/strong><\/p>\n Despite common clinical practice, patients receiving prior or concurrent corticosteroids achieved similar rates of hair regrowth compared with those treated with baricitinib alone.<\/p>\n 2. Baricitinib monotherapy was just as well tolerated as combination therapy, suggesting that routine addition of systemic corticosteroids may not provide meaningful long-term benefit.<\/strong><\/p>\n Both strategies had comparable adverse event rates, although pneumonia occurred only in the corticosteroid combination group. <\/p>\n Alopecia areata is a common autoimmune disease in which systemic corticosteroids are often prescribed at treatment initiation to rapidly suppress disease activity while waiting for Janus kinase (JAK) inhibitors such as baricitinib to take effect. However, it has remained unclear whether this approach actually improves long-term outcomes. In this retrospective cohort study, investigators compared 35 patients treated with baricitinib alone with 32 patients who received short-course systemic corticosteroids before or alongside baricitinib. After 24 weeks of treatment, patients in both groups achieved remarkably similar rates of hair regrowth, including comparable improvements in Severity of Alopecia Tool (SALT) scores, similar times to response, and nearly identical safety profiles. These findings suggest that routine corticosteroid “bridging” therapy may not provide additional long-term benefit beyond baricitinib alone. <\/p>\n This study suggests that prior or concurrent short-course systemic corticosteroids do not significantly enhance the effectiveness of baricitinib in patients with moderate-to-severe alopecia areata.<\/p>\n Patients receiving baricitinib alone achieved similar rates of meaningful hair regrowth, including SALT30, SALT50, SALT90, SALT \u226420, and SALT \u226410 outcomes.<\/p>\n The safety profiles of the two treatment strategies were also comparable, although pneumonia occurred only in the combination therapy group.<\/p>\n Overall, these findings support the use of baricitinib as an effective standalone systemic treatment for many patients with moderate-to-severe alopecia areata, while emphasizing that larger prospective studies are still needed to determine whether certain patient subgroups may benefit from combination therapy. <\/p>\n<\/div>\nOVERVIEW OF STUDY<\/strong><\/h3>\n
CONCLUSIONS<\/strong><\/h3>\n